trendingnewswithaditi

China accounted for around 67% of India’s bulk drug imports in FY19 The import of bulk drugs and drug intermediates from China stood at $2,055.94 million in 2017-18, accounting for 68.68 per cent of their total import International :- China represented 67.56 percent of all out imports of mass medications and medication intermediates in 2018-19 at $2,405.42 million, Parliament was educated on Tuesday. The import of mass medications and medication intermediates from China remained at $2,055.94 million of every 2017-18, representing 68.68 percent of their complete import, Minister of Chemicals and Fertilizers D V Sadananda Gowda said in an answer to the Lok Sabha. Refering to information from DGCIS Kolkata, he said portion of China in the absolute mass medication imported to the nation during 2018-19 was around 67 percent. “The nation imports mass medications/dynamic pharmaceutical fixings (APIs) for delivering prescriptions including certain fundamental drugs. As India i...

Domestic market growth helping Indian pharma cos offset pricing pressure in US: Fitch Current Affair :-Rising incomes in the residential market has helped Indian pharma organizations balance the progressing evaluating weight on conventional medications in the US in the budgetary year finished March 31, Fitch Ratings said Monday. The US and India are the two key markets served by Indian pharmaceutical organizations, which sell prevalently nonexclusive medications, Fitch Ratings said in an announcement. A large number of the main pharmaceutical organizations announced twofold digit development in their household deals which thusly upheld generally speaking industry development of 11 percent amid FY19, it included. “Conversely, development in the US market stayed stifled for some Indian drugmakers, as combination of pharma merchants and a quicker pace of endorsements of new nonexclusive medications by the US Food and Drug Administration (USFDA) has brought about proceeded...

Domestic market growth helping Indian pharma cos offset pricing pressure in US: Fitch Current Affair :-Rising incomes in the residential market has helped Indian pharma organizations balance the progressing evaluating weight on conventional medications in the US in the budgetary year finished March 31, Fitch Ratings said Monday. The US and India are the two key markets served by Indian pharmaceutical organizations, which sell prevalently nonexclusive medications, Fitch Ratings said in an announcement. A large number of the main pharmaceutical organizations announced twofold digit development in their household deals which thusly upheld generally speaking industry development of 11 percent amid FY19, it included. “Conversely, development in the US market stayed stifled for some Indian drugmakers, as combination of pharma merchants and a quicker pace of endorsements of new nonexclusive medications by the US Food and Drug Administration (USFDA) has brought about proceeded...